Company*
(Country; Symbol)

University/
Nonprofit@

Type Of
Agreement

Product Area

Details (Date)


Acceptys Inc.*

University of Wurzburg (Germany)

Research agreement

University researchers will further characterize about 650 anticancer human antibodies

The deal followed one in which Acceptys acquired rights to develop antibodies from OncoMab GmbH, which was formed from university research (12/23)

Accentia Bio-
pharmaceuticals
Inc.
(ABPI)

Mayo Foundation for Medical Education and Research

Option agreement

The option covers a method of using anti-fungals applied intranasally for treating chronic sinusitis

Accentia has exclusive rights to negotiate a license until Dec. 6, 2006; the method covers all anti-fungals except amphotericin B (12/15)

ACE BioSciences
A/S*
(Denmark)

Aeras Global TB Vaccine Foundation

Collaboration

ACE will support characterization of a BCG- based tuberculosisvaccine

ACE will identify and characterize proteins in the second-generation vaccine Aeras is developing; terms were not disclosed (12/19)

Affymetrix Inc.
(AFFX)

Duke University

Collaboration

Five-year deal to analyze genomic information across large patient samples

Duke researchers will use Affymetrix microarray technology to develop new applications for translational research projects; the initial focus is on cancer and cardiovascular disease (1/9)

Affymetrix Inc.
(AFFX)

Imperial College London and the Medical Research Council (UK)

Collaboration

To discover genetic variations associated with cancer, diabetes and cardiovascular disease

College and MRC researchers will use Affymetrix's GeneChip technology in the deal, which is part of Affymetrix's translational medicine program (12/14)

Amorfix Life
Sciences Ltd.
(Canada; CDNX:AMF)

University of Toronto (Canada)

License agreement

Amorfix got worldwide rights to targets on the protein superoxide dismutase-1

Amorfix also got a five-year option to acquire the technology, which will be tested against amyotrophic lateral sclerosis and other neurodegenerative diseases (2/2)

Aphios Corp.*

Boston University Medical School

License agreement

Aphios got rights to a nontoxic vitamin D analogue

The compound is being developed for prostate cancer; terms of the deal were not disclosed (12/13)

Artemis
Pharmaceuticals
GmbH
(Germany;
subsidiary of
Exelixis Inc.; EXEL)

Medical Research Council Protein Phosphorylation Unit (UK)

License agreement

Artemis got rights to use and distribute certain genetically engineered mouse models

Artemis will distribute the kinase models to companies and instituions and can use them in its programs; terms were not disclosed (12/5)

AvidBiotics
Corp.*

University of California at San Diego

License agreement

AvidBiotics got worldwide rights to protein scaffold technology

The technology centers on a ligand-binding protein scaffold that accommodates 10 trillion sequences (2/23)

Biocortech*
(France)

Columbia University

Collaboration

Deal for research involving the mRNA editing of the serotonergic receptor

They also plan to identify therapeutic targets; the focus is on treating depression (2/23)

Bioheart Inc.*

Cleveland Clinic

License agreement

Bioheart got rights to technology related to the repair of scarred heart tissue damaged from a heart attack

The patent applications cover methods of repairing tissue by transplanting muscle stem cells that express therapeutic proteins capable of recruiting other stem cells to the area (2/20)

BioLineRx
Ltd.*
(Israel)

The Technion Research and Development Foundations (Israel)

License agreement

BioLineRx got rights to the antibiotic candidate BL-2060

The antibacterial peptide is designed to kill bacteria without causing hemolysis; terms were not disclosed (1/16)

BioLineRx
Ltd.*
(Israel)

Tel Aviv University (Israel)

License agreement

BioLineRx got rights to BL-2050, an agent for treating peripheral vascular disease

The agent acts through a non- VEGF pathway; terms of the deal were not disclosed (1/16)

BioVeris Corp.
(BIOV)

University of Massachusetts at Amherst

License agreement

BioVeris exercised its option to exclusively license a vaccine candidate for Chlamydia

UMA gets a $75,000 license fee and potential milestone payments, as well as royalties on any resulting sales (12/6)

BioVeris Corp.
(BIOV)

Jewish General Hospital (Canada)

License agreement

BioVeris got exclusive rights to use a JGH database containing infectious disease information

The database has demographic data and the serologic status on an immigrant population; BioVeris paid a $50,000 license fee and will sponsor $400,000 of research at JGH over three years (11/21)

Calando
Pharmaceuticals
Inc.*
(majority
owned by Arrow-
head Research
Corp.; ARWR)

National Cancer Institute

Collaboration

The deal focuses on developing RNAi therapeutics for treating neuroblastoma

They will share responsibilities in the research program, which is expected to run at least three years; a CRADA covering the deal was being finalized (2/3)

Callisto
Pharmaceuticals
Inc.
(AMEX:KAL)

University of Texas M.D. Anderson Cancer Center

License agreement

Callisto got rights to a new class of cancer drugs called Degrasyns

The agents are designed to induce tumor cell death; terms of the deal were not disclosed (1/25)

Can-Fite
BioPharma Inc.
(Israel; TEL:CFBI)

National Institutes of Health

CRADA

Deal to identify agonists of the adenosine A3 receptor

The goal is to identify agents for treating autoimmune diseases and cancer (1/24)

Cellegy
Pharmaceuticals
Inc.
(OTC BB:CLGY)

Contraceptive Research and Development Organization

License agreement

CONRAD licensed rights to Cellegy's entire microbicide pipeline

The nonexclusive agreement covers the developing world; products include Savvy, UC-781 and Cyanovirin-N (2/1)

Cel-Sci Corp.
(AMEX:CVM)

National Institute of Allergy and Infectious Diseases

Cooperative agreement

Deal to test Cel-Sci's anti- infective drug CEL-1000 in animal models against the H5N1 avian flu virus

The agent is believed to activate immune responses; terms of the deal were not disclosed (12/5)

Cepheid Inc.
(CPHD)

Public Health Agency of Canada's National Microbiology Laboratory

Collaboration

Deal to develop in-field nucleic acid assays for Ebola, Marburg and Lassa fever viruses

They will use Cepheid's Gene- Xpert technology in the effort; Cepheid will have rights to resulting technology (2/14)

Ceragenix
Pharmaceuticals
Inc.
(OTC BB:CGXP)

Centers for Disease Control and Prevention

CRADA

Deal to evaluate Ceragenix's Ceracide for preventing bacterial biofilm growth on medical devices

The antimicrobial coating will be evaluated in the CDC's Biofilm Reactor; terms of the deal were not disclosed (2/8)

Chemokine
Therapeutics
Corp.
(Canada;
OTC BB:CHKT)

University of Texas M.D. Anderson Cancer Center

Agreement

The cancer center will conduct tests of Chemokine's CTCE- 908 product

The agent will be studied for its ability to inhibit metastasis of a human breast cancer in preclinical models (2/21)

Chemokine
Therapeutics
Corp.
(Canada;
OTC BB:CHKT)

Dana-Farber Cancer Institute

Material transfer agreement

Deal under which Chemokine will supply its CTCE-9908 product to Dana-Farber

The institute will investigate the drug's ability to inhibit growth of human brain cancer cells in pre-clinical experiments (2/16)

Chemokine
Therapeutics
Corp.
(Canada;
OTC BB:CHKT)

National Cancer Institute

Material transfer agreement

Deal under which Chemokine will supply its CTCE-9908 product to the NCI

The NCI will investigate the role of CTCE- 908 in the pathology of primary effusion lymphoma; terms were not disclosed (2/13)

Ciphergen
Biosystems Inc.
(CIPHE)

University of Texas Medical Branch at Galveston

Collaboration

Deal to apply Ciphergen technologies to UTMB clinical samples for liver disease research

They intend to develop a diagnostic blood test for measuring the progress of liver disease; Ciphergen gets first right to license resulting products (11/21)

Clinical Data Inc.
(CLDA)

University of Pittsburgh Cancer Institute

Collaboration

Deal to perform a metabolomics study in lung cancer patients

The goal of the pilot study is to evaluate the suitability of meta-bolomics for cancer detection and screening (1/12)

CombiMatrix
Group
(CBMX)

U.S. Air Force Research Laboratory

CRADA

Deal to develop a miniaturized device for monitoring the health status of military personnel

They will use CombiMatrix's CustomArray technology to develop a device capable of analyzing multiple biomarkers (2/23)

CombiMatrix
Group
(CBMX)

University of Colorado Health Sciences Center

Agreement

Deal under which university researchers can purchase microarray technology

The nonexclusive deal was made under CombiMatrix's CombiCore access program; terms were not disclosed (1/6)

CombiMatrix
Group
(CBMX)

University of California at Los Angeles

Collaboration

Deal to develop a gene-based test for the diagnosis of malignant melanoma

UCLA researchers also will provide patient samples for the development and validation phase of the project (12/7)

Corautus
Genetics Inc.
(VEGF)

Caritas St. Elizabeth's Medical Center

Agreement

Corautus will provide its VEGF-2 product for a trial being run by CSEMC

The Phase I trial, funded by an NIH grant, is focused on critical limb ischemia (1/11)

Crucell NV
(the Netherlands;
CRXL)

Walter Reed Army Institute of Research

CRADA

Deal to evaluate Crucell's PER.C6 technology for development of vaccines against certain flaviviruses

WRAIR will evaluate the technology in vaccines against dengue fever and Japanese encephalitis; terms were not disclosed (12/22)

Crucell NV
(the Netherlands;
CRXL)

Saskatchewan Research Council (Canada)

Manufacturing agreement

SRC got rights to sell PER.C6 cell line services in Canada; SRC also got a license to the technology

The services are for manufacturing gene therapy and vaccine products; Crucell gets a license fee, annual maintenance fees and royalties on sales (12/22)

CytoCore Inc.
(OTC BB: MCDG)

University Hospitals of Cleveland

License agreement

CytoCore got rights to a drug delivery system

The system is designed to allow application of approved drugs to existing cervical lesions (2/23)

CytoCore Inc.
(OTC BB: MCDG)

University Hospitals of Cleveland

License agreement

CytoCore got rights to the cancer biomarker CGI5

Terms of the deal on the apoptosis marker were not disclosed (2/17)

CytRx Corp.
(CYTR)

University of Massachusetts Medical School

Expanded agreement

The new deal covers drug targets that regulate insulin activity in fat cells

CytRx licensed the targets, which were discovered in an existing collaboration between it and UMMS (12/15)

Eurand
International
SpA*
(Italy)

Universities of Milan and Sassari (both in Italy)

License agreement

Eurand got an option to develop a class of analgesic compounds

They will collaborate to develop and evaluate the five compounds for the treatment of pain (1/24)

Exelixis Plant
Sciences Inc.
(unit of Exelixis
Inc.; EXEL)

Washington State University Research Foundation

License agreement

Exelixis will use its technologies to develop methods for producing paclitaxel and taxane intermediates

Exelixis has advanced developments of its taxane cell factory program under a previous license from WSURF; terms were not disclosed (12/28)

454 Life
Sciences Corp.
(majority owned
by CuraGen Corp.;
CRGN)

The Broad Institute

Collaboration

The institute will conduct genomic studies relating to the genetic basis for complex diseases

The institute will use a genome sequencer system from 454 in the effort; terms of the deal were not disclosed (12/19)

Galapagos NV
Belgium; (Euronext:GLPG)

Cancer Research Technology (UK)

Collaboration

Galapagos will provide medicinal chemistry services for CRT anti-cancer drug programs

CRT will fund the work for four scientists at Galapagos' service division, BioFocus, through 2006 (1/19)

Gammacan
International Inc.
(Israel; OTC BB:GCAN)
Services Ltd.
(Israel)

Tel Hashomer Medical Research Infrastructure and treatment

Research and license agreement

To explore mechanisms of action of IVIg and its uses in cancer

Terms of the deal were not disclosed (12/20)

GeoPharma Inc.*

University of Florida

License agreement

GeoPharma got rights to a compound for treating primary or idiopathic pulmonary hypertension

The compound is a synthetic peptide in preclinical testing; terms of the deal were not disclosed (1/31)

Hemispherx
Biopharma
Inc.
(AMEX:HEB)

Canadian Department of National Defence

Research agreement

To evaluate antiviral efficacy of the company's Ampligen and Alferon products

Defence R&D Canada is testing the products against influenza in an effort focused on the bird flu (11/29)

HemoBioTech
Inc.
(OTC BB:HMBT)

Texas Tech University Health Sciences Center

Sponsored research agreement

The agreement centers on the manufacture of clinical-grade HemoTech

They entered the third-stage of an agreement on the blood substitute product; terms were not disclosed (1/18)

Humanetics
Corp.*

Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.

License agreement

Deal to develop the oral agent BIO300 for protecting the immune system against radiation exposure

Humanetics assumed responsibility for continued testing, development and commercialization of the product; terms were not disclosed (12/8)

Humanetics
Corp.*

Mount Sinai School of Medicine

License agreement

Humanetics got rights to NIC5-15, a preclinical agent being developed for Alzheimer's disease

They also agreed to a deal under which Mount Sinai will test the agent in humans; terms were not disclosed (12/1)

Hybrigenics
SA*
(France)

Genethon (France)

Collaboration

Genethon will use Hybrigenics technology in research in muscle cell proteins and their interaction

Hybrigenics will use screening and protein interaction mapping software in the effort; Genethon will own resulting data; terms were not disclosed (12/21)

Illumina Inc.
(ILMN)

Center for Inherited Disease Research

Collaboration

CIDR will use Ilumina genotyping technology in a pilot study in Type II diabetes

One goal is to evaluate the technology for possible adoption as the standard platform for CIDR's genome-wide association service (1/11)

Immtech
International Inc.
(AMEX:IMM)

Tulane University

License agreement

Immtech got rights to a class of aminoquinoline drugs for treating and diagnosing infectious diseases

The lead compound, AQ13, is targeted for the treatment of, and as a prophylaxis for, malaria; terms of the exclusive deal were not disclosed (2/10)

Immusol Inc.*

Baylor College of Medicine

License agreement

Immusol got rights to an oncolytic viral therapy that uses herpes simplex viruses against cancer

Terms of the exclusive, worldwide deal were not disclosed (2/1)

Innovive
Pharmaceuticals
Inc.*

Memorial Sloan- Kettering Cancer Center

License agreement

Innovive got rights to a WT1 heteroclitic peptide immuno- therapeutic, INNO-305

Phase I trials are expected to start in the first half of 2006; the agent targets most leukemias and certain solid tumors (1/9)

Invitrogen
Corp.
(IVGN)

Families of Spinal Muscular Atrophy

Collaboration

To identify targets linked to causes and symptoms of spinal muscular atrophy

Invitrogen will use its protein microarray technology in the intial stages of the deal; terms were not disclosed (12/21)

Lumera Corp.
(LMRA)

Medical University of South Carolina

Agreements

Deal to co-develop a protein chip aimed at the drug discovery and toxicology market

Also, letter of intent calls for MUSC to purchase a Proteomic-Processor Biosensor instrument; terms were not disclosed (2/6)

Lumera Corp.
(LMRA)

Harvard Medical School

Collaboration

Deal to develop a next- generation silicon chip substrate

The goal is to develop 10,000- spot very high density protein arrays (1/9)

Medicure Inc.
(Canada; AMEX:
MCU)

Loyola University Stritch School of Medicine

Collaboration expansion

Deal to conduct further preclinical studies of Medicure's antithrombotic agents

The goal is to advance a lead clinical candidate into human studies; terms of the deal were not disclosed (1/5)

MedImmune Inc. (MEDI)

Burnham Institute for Medical Research

License agreement

Deal to develop peptides targeting the EphA and EphB subfamilies of receptor tyrosine kinases

MedImmune would develop and market any resulting products; Burnham gets an up- front fee and potential milestone and royalty payments (12/8)

MedImmune
Inc.
(MEDI)

Mount Sinai School of Medicine

License agreement

MedImmune got exclusive rights to certain reverse genetics technology

Mount Sinai gets an up-front fee and potential milestone and royalty payments; the technology will be used to improve the efficiency of producing new influezna vaccine strains (12/7)

Memory
Pharmaceuticals
Corp.
(MEMY)

The Stanley Medical Research Institute

Funding support

The institute will help fund trials of Memory's MEM 1003 for treating bipolar disorder

The neuronal L-type calcium channel modulator is nearing Phase IIa trials in that indication; Memory is eligible to receive up to $3.2M in the deal (12/20)

Metabolon
Inc.*

University of Michigan

Collaboration

They will work to discover disease biomarkers for prostate cancer

The deal marks Metabolon's first project as part of the NCI's Early Detection Research Network; the project is funded by an NCI grant (11/30)

MicroIslet
Inc.
(AMEX:MII)

Mayo Foundation for Medical Education and Research

Supply agreement

Mayo will supply pathogen- free pigs to MicroIslet for use in development of a product for diabetes

Pig islets will be used in the MicroIslet-P product; MicroIslet also got rights to use the pigs for research and treatment in diabetes under the long-term deal (11/22)

Minster
Pharmaceuticals
plc
(UK; AIM:MPM)

University of Copenhagen and the Danish Headache Centre

Collaboration

Deal to investigate the use of tonabersat in the prevention of migraine with aura

A planned Phase II trial is part of a broader deal to investigate the mechanisms underlying migraine (1/13)

Morphotek
Inc.*

National Cancer Institute

License agreement

Morphotek got rights to an antibody targeting mesothelin- expressing cancers

The rights cover diagnostic and therapeutics applications; initial trials of the antibody, MORAb-009, were planned for early in 2006 (1/3)

MultiCell
Technologies
Inc.
(OTC BB:MCET)

Columbia University Medical Center

Research agreement

Deal to perform in vivo tests on an agent for protecting against retinal ganglion cell death

MultiCell will fund research and have an exclusive option to resulting discoveries; the focus is on ocular neurodegenerative diseases (12/1)

NanoMed
Pharmaceuticals
Inc.*

University of Kentucky

Option agreement

NanoMed will evaluate raspberry gels for treating and preventing oral epithelial dysplasia

NanoMed intends to start trials in humans; Ohio State University also was a party to the exclusive option agreement (12/13)

NovaThera Ltd.*
(UK)

Imperial College London and The Texas Heart Institute

Collaboration

They established a program to scale up supply of human heart cells for clinical trials

Using bioprocessor technology, the group intends to develop processes for the practical manufacture of cells for medical uses (12/12)

Novavax Inc.
(NVAX)

University of Pittsburgh School of Medicine

Collaboration

Deal to evaluate the efficacy of virus-like particle influenza vaccines

They also will test Novasomes as an adjuvant; studies in humans were expected to begin later in 2006 (2/15)

Novelix
Pharmaceuticals
Inc.*

University of Southern California

License agreement

Novelix got exclusive rights to a group of potential cancer therapeutics

The lead compound, NVX-144, is expected to enter clinical trials late in 2006; terms of the deal were not disclosed (12/19)

Open Biosystems
Inc.*

Four cancer centers

Agreement

The centers adopted the company's short hairpin RNA technology for use in cancer research

Duke University, the National Cancer Institute, Lee Moffitt Cancer Center and Fox Chase Cancer Center adopted the technology (12/19)

Orion Genomics*

University of Glasgow (UK)

Collaboration

To develop epigenetic biomarkers for tests to screen for cancer and to help guide treatment

They will use Orion's methylation technologies to identify biomarkers in cancers of the lung, breast and ovaries (1/20)

Orion Integrated
Biosciences Inc.*

Virginia Bioinformatics Institute

Agreement

Deal to develop diagnostic methods for certain viral pathogens

Data on encephalic and hemorrhagic viruses from VBI's PathPort project will be integrated into Orion's computational tool (2/7)

Peregrine
Pharmaceuticals
Inc.
(PPHM)

Sidney Kimmel Cancer Center

Manufacturing agreement

Peregrine subsidiary Avid Bioservices Inc. will perform manufacturing services for SKCC

Avid will provide services related to an antibody initially being developed for lung cancer (12/22)

PharmaFrontiers
Corp.
(OTC
BB:PFTR)

Shanghai Institutes for Biological Sciences (China)

License agreement

PharmaFrontiers got worldwide rights to an autologous T-cell vaccine

The vaccine targets rheumatoid arthritis; SIBS gets an up-front payment and royalties on any resulting sales(1/17)

Point
Therapeutics
Inc.
(POTP)

National Cancer Institute

Collaboration

Deal to evaluate Point's talabostat in pediatric patients with solid tumors

A Phase I trial is being planned to evaluate safety and dosing of the oral agent with chemotherapy (2/14)

PsychoGenics
Inc.*

Spinal Muscular Atrophy Foundation

Agreement extension

Deal to establish and behaviorally phenotype transgenic in vivo models of SMA

They also plan to test potential therapeutics using those models (2/24)

QBI Life
Sciences
(division
of Quintessence
Biosciences Inc.*)

University of Wisconsin and the University of Helsinki (Finland)

Partnership

Deal to develop a high- throughput molecular screening platform for membrane protein targets

The work is being funded by a $175,000 grant under the National Institutes of Health's Roadmap for Medical Research program (1/19)

Rexahn
Pharmaceuticals
Inc.*

University of Maryland

Collaboration

Deal to develop drugs for treating cancer and central nervous system diseases

Rexahn and UM's Center for Nanomedicine and Cellular Delivery will use nanotechnologies in the effort (2/23)

Samaritan
Pharmaceuticals
Inc.
(AMEX:LIV)

Georgetown University

License agreement

Samaritan got exclusive rights to the use of spirostenols to treat mitochondrial disorders

Terms of the deal were not disclosed (2/2)

Savient
Pharmaceuticals
Inc.
(SVNTE)

University of California at San Diego

License termination

Savient ended a deal covering development of Prosaptide

The decision was made following a failed Phase II trial in patients with HIV-associated peripheral neuropathy (12/22)

Stem Cell
Sciences plc
(UK; AIM:STEM)

University of Edinburgh

Technology transfer agreement

Deal to continue their collaboration in stem cell research

They have collaborated since 1994; SCS retains all licenses issued under the previous deal (1/31)

Transgene SA
(France; Eurolist:
FR0005175080)

International AIDS Vaccine Initiative

Manufacturing agreement

Transgene will manufacture an AIDS vaccine candidate for use in clinical trials

Transgene will use its viral vectors process in the effort; terms of the 18-month contract were not disclosed (11/17)

20/20
GeneSystems
Inc.*

University of Kentucky

License agreement

20/20 got rights to a a blood test for non-small-cell lung cancer

20/20 intends to create a screening test for the early detection of lung cancer based on biomarkers identified by UK (12/15)

Vertex
Pharmaceuticals
Inc.
(VRTX)

Cystic Fibrosis Foundation Therapeutics Inc.

Collaboration extension

Vertex will continue research on "corrector" compounds that restore the function of the CFTR protein

CFFT will provide another $22M to Vertex through early 2008; the original deal began in 2000; CFFT would get royalties on any resulting sales (1/12)

Vical Inc.
(VICL)

Stanford, Harvard and Yale universities

License agreements

The universities got nonexclusive access to Vical's DNA delivery technology

The academic licenses allow free use of the technology; Vical would have the option to license resulting applications (1/24)

ViroPharma
Inc.
(VPHM)

Hines VA Hospital

License agreement

ViroPharma got rights to non-toxigenic strains of C. difficile to treat and prevent C. difficile-associated disease

ViroPharma's initial focus is on preventing recurrence of CDAD following Vancocin treatment (2/27)

Viropro Inc.
(Canada; OTC BB:
VPRO)

Biotechnology Research Institute (Canada)

Collaboration

Deal to develop production procedures for biological materials and drugs

The intent is to market recombinant proteins and a new vaccination platform (12/1)

Xechem
International
Inc.
(OTC BB:XKEM)

Virginia Commonwealth University

License agreement

Xechem got rights to a five-membered hetero-cyclic anti-sickling compound

The compound will be studied for treating sickle cell disease; terms of the exclusive license were not disclosed (12/9)

Xencor Inc.*

University of Cambridge (UK)

License agreement

Xencor got rights to technology for creating monoclonal antibodies with enhanced potency

The technology includes specific Fc variants that complement Xencor's XmAb engineered Fc domains; terms of the exclusive deal were not disclosed (12/14)

Zenyth
Therapeutics
Ltd.
(Australia;
ASX:ZTL)

Ludwig Institute for Cancer Research (Germany)

License agreement

Zenyth got rights to antibodies that target the receptor for granulocyte-colony stimulating factor

Zenyth also got access to antibodies and reagents developed at the institute's Melbourne branch (2/28)


Notes:
This chart does not include grants or contract awards, or agreements between biotech companies and clinical trial centers.
* Denotes privately held company.
@ Some institutions listed have for-profit components. They are located in the U.S. unless otherwise noted.
CRADA = Cooperative Research and Development Agreement.
Unless otherwise noted, shares are traded on the Nasdaq exchange.
AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CDNX = Canadian Venture Exchange; OTC BB = Over-the-Counter Bulletin Board; TEL = Tel Aviv Stock Exchange; TSE = Toronto Stock Exchange.

No Comments